Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.

Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L.

Clin Cancer Res. 2019 Dec 4. doi: 10.1158/1078-0432.CCR-19-1635. [Epub ahead of print]

PMID:
31801732
2.

Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial.

Henselmans I, van Laarhoven HWM, van Maarschalkerweerd P, de Haes HCJM, Dijkgraaf MGW, Sommeijer DW, Ottevanger PB, Fiebrich HB, Dohmen S, Creemers GJ, de Vos FYFL, Smets EMA.

Oncologist. 2019 Nov 26. pii: theoncologist.2019-0453. doi: 10.1634/theoncologist.2019-0453. [Epub ahead of print]

PMID:
31771987
3.

Molecular tools for the pathologic diagnosis of central nervous system tumors.

Priesterbach-Ackley LP, Wesseling P, Snijders TJ, de Vos FYFL, de Leng WWJ.

Neurooncol Pract. 2019 Jan;6(1):4-16. doi: 10.1093/nop/npy041. Epub 2018 Nov 5. Review.

PMID:
31386041
4.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

5.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

6.

Promoting shared decision making in advanced cancer: Development and piloting of a patient communication aid.

Henselmans I, Brugel SD, de Haes HCJM, Wolvetang KJA, de Vries LM, Pieterse AH, Baas-Thijssen MCM, de Vos FYF, van Laarhoven HWM, Smets EMA.

Patient Educ Couns. 2019 May;102(5):916-923. doi: 10.1016/j.pec.2018.12.018. Epub 2018 Dec 14.

PMID:
30591283
7.

An assisted structured reflection on life events and life goals in advanced cancer patients: Outcomes of a randomized controlled trial (Life InSight Application (LISA) study).

Kruizinga R, Scherer-Rath M, Schilderman JB, Hartog ID, Van Der Loos JP, Kotzé HP, Westermann AM, Klümpen HJ, Kortekaas F, Grootscholten C, Bossink F, Schrama J, Van De Vrande W, Schrama NA, Blokland W, De Vos FY, Kuin A, Meijer WG, Van Oijen MG, Sprangers MA, Van Laarhoven HW.

Palliat Med. 2019 Feb;33(2):221-231. doi: 10.1177/0269216318816005. Epub 2018 Dec 5. No abstract available.

8.

Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies.

Noorlag L, De Vos FY, Kok A, Broekman MLD, Seute T, Robe PA, Snijders TJ.

Clin Nutr. 2019 Oct;38(5):1986-1994. doi: 10.1016/j.clnu.2018.10.024. Epub 2018 Nov 14. Review.

PMID:
30473444
9.

Symptom Monitoring in Glioma Patients: Development of the Edmonton Symptom Assessment System Glioma Module.

IJzerman-Korevaar M, Snijders TJ, Teunissen SCCM, de Graeff A, De Vos FYF.

J Neurosci Nurs. 2018 Dec;50(6):381-387. doi: 10.1097/JNN.0000000000000400.

PMID:
30407970
10.

Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review.

IJzerman-Korevaar M, Snijders TJ, de Graeff A, Teunissen SCCM, de Vos FYF.

J Neurooncol. 2018 Dec;140(3):485-496. doi: 10.1007/s11060-018-03015-9. Epub 2018 Oct 30.

11.

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.

Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.

Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15.

PMID:
30324586
12.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
13.

Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial.

Henselmans I, van Laarhoven HWM, de Haes HCJM, Tokat M, Engelhardt EG, van Maarschalkerweerd PEA, Kunneman M, Ottevanger PB, Dohmen SE, Creemers GJ, Sommeijer DW, de Vos FYFL, Smets EMA.

Oncologist. 2019 Feb;24(2):259-265. doi: 10.1634/theoncologist.2018-0090. Epub 2018 Jun 29.

PMID:
29959285
14.

Length of Thromboprophylaxis in Patients Operated on for a High-Grade Glioma: A Retrospective Study.

Senders JT, Snijders TJ, van Essen M, van Bentum GM, Seute T, de Vos FY, Smith TR, Robe PA, Broekman MLD.

World Neurosurg. 2018 Jul;115:e723-e730. doi: 10.1016/j.wneu.2018.04.151. Epub 2018 Apr 30.

PMID:
29715571
15.

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.

van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE.

Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24.

PMID:
29574584
16.

A randomized controlled trial of a skills training for oncologists and a communication aid for patients to stimulate shared decision making about palliative systemic treatment (CHOICE): study protocol.

Henselmans I, Smets EMA, de Haes JCJM, Dijkgraaf MGW, de Vos FY, van Laarhoven HWM.

BMC Cancer. 2018 Jan 8;18(1):55. doi: 10.1186/s12885-017-3838-8.

17.

Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.

van der Vlist A, Snijders TJ, Stades AME, Spliet WGM, De Vos FYFL.

Neth J Med. 2017 Dec;75(10):451-454.

18.

Venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis.

Senders JT, Goldhaber NH, Cote DJ, Muskens IS, Dawood HY, De Vos FYFL, Gormley WB, Smith TR, Broekman MLD.

J Neurooncol. 2018 Jan;136(1):135-145. doi: 10.1007/s11060-017-2631-5. Epub 2017 Oct 16.

19.

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.

Cirkel GA, Kerklaan BM, Vanhoutte F, Van der Aa A, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, Voest EE, Schellens JH, Lolkema MP.

Invest New Drugs. 2016 Apr;34(2):184-92. doi: 10.1007/s10637-015-0320-9. Epub 2016 Jan 20.

20.

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, van den Bent MJ.

Br J Cancer. 2015 Jul 14;113(2):226-31. doi: 10.1038/bjc.2015.191. Epub 2015 Jun 4.

21.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ; Dutch Neuro-Oncology Group (LWNO).

Eur J Cancer. 2015 Jul;51(10):1321-30. doi: 10.1016/j.ejca.2015.03.025. Epub 2015 Apr 17.

PMID:
25899986
22.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
23.

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy.

De Vos FY, Middelburg TA, Seynaeve C, de Jonge MJ.

Kansenshogaku Zasshi. 2014 May;88(3 Suppl 9-10):37-9.

PMID:
24979953
24.

Diagnostic challenges of respiratory adverse events during everolimus treatment.

Willemsen AE, De Vos FY, Jansen A, de Boer M, Tjan-Heijnen VC, van Herpen CM.

Target Oncol. 2014 Sep;9(3):287-91. doi: 10.1007/s11523-014-0310-4. Epub 2014 Mar 5.

PMID:
24590692
25.

FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases.

De Vos FY, Mulder SF, Drenth JP, Nagtegaal ID, Fütterer JJ, van der Graaf WT.

BMC Cancer. 2013 Oct 22;13:491. doi: 10.1186/1471-2407-13-491.

26.

Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.

De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM.

Crit Rev Oncol Hematol. 2013 Mar;85(3):373-82. doi: 10.1016/j.critrevonc.2012.08.002. Epub 2012 Aug 25. Review.

PMID:
22925496
27.

Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline.

De Vos FY, van Laarhoven HW, Laven JS, Themmen AP, Beex LV, Sweep CG, Seynaeve C, Jager A.

Crit Rev Oncol Hematol. 2012 Nov;84(2):252-60. doi: 10.1016/j.critrevonc.2012.06.005. Epub 2012 Jul 12. Review.

PMID:
22795229
28.

Taxus baccata allergy in a breast cancer patient.

de Vos FY, van Laarhoven HM.

Neth J Med. 2012 Jun;70(5):249-0. No abstract available.

29.

Cetuximab-induced pneumonitis in head and neck cancer patient.

De Vos FY, Driessen CM, Jaspers HC, van Herpen CM, Simons B.

Oral Oncol. 2012 Jun;48(6):e17-8. doi: 10.1016/j.oraloncology.2012.01.023. Epub 2012 Feb 17. No abstract available.

PMID:
22342570
30.

Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.

de Vos FY, de Wit R.

Ther Adv Med Oncol. 2010 Nov;2(6):381-8. doi: 10.1177/1758834010376185.

31.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH.

J Clin Oncol. 2011 Aug 20;29(24):3240-6. doi: 10.1200/JCO.2010.32.9839. Epub 2011 Jul 18.

PMID:
21768449
32.

Combined therapy for thyroid squamous cell carcinoma.

De Vos FY, Sewnaik A, de Wilt JH, Smid EJ, den Bakker MA, van Meerten E.

Head Neck. 2012 Jan;34(1):131-4. doi: 10.1002/hed.21484. Epub 2010 Jul 22.

PMID:
20652981
33.

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy.

De Vos FY, Middelburg TA, Seynaeve C, de Jonge MJ.

J Infect Chemother. 2010 Feb;16(1):59-61. doi: 10.1007/s10156-009-0017-0.

PMID:
20054603
34.

Histiocytic sarcoma localised in the thyroid: a case report.

De Vos FY, Gerding MN, Arends JW, Wegman JJ.

Ann Hematol. 2008 Aug;87(8):681-2. doi: 10.1007/s00277-008-0473-0. Epub 2008 Apr 3. No abstract available.

35.

[The portfolio will increase the quality of specialist education].

Sluiter HE, de Vos FY, Wever-Kroes EM.

Ned Tijdschr Geneeskd. 2007 Feb 24;151(8):492. Dutch.

PMID:
17378308
36.

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA.

Ann Oncol. 2006 Aug;17(8):1320-7. Epub 2006 May 25.

PMID:
16728485
37.

Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.

Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G.

Clin Cancer Res. 2006 Mar 15;12(6):1760-7.

38.

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.

Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA.

Eur J Cancer. 2006 Mar;42(4):467-72. Epub 2006 Jan 10.

PMID:
16406507
39.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.

Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG.

J Clin Oncol. 2005 Aug 1;23(22):5188-97.

PMID:
16051960
40.

A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.

De Vos FY, Bos AM, Schaapveld M, de Swart CA, de Graaf H, van der Zee AG, Boezen HM, de Vries EG, Willemse PH.

Gynecol Oncol. 2005 Apr;97(1):60-7.

PMID:
15790438
41.

A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.

Bos AM, De Vos FY, de Vries EG, Beijnen JH, Rosing H, Mourits MJ, van der Zee AG, Gietema JA, Willemse PH.

Eur J Cancer. 2005 Mar;41(4):539-48. Epub 2005 Jan 11.

PMID:
15737558
42.

Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.

de Vos FY, Willemse PH, de Vries EG, Gietema JA.

Cancer Treat Rev. 2004 Oct;30(6):495-513. Review.

PMID:
15325031
43.

Successful treatment of metastatic esthesioneuroblastoma.

de Vos FY, Willemse PH, de Vries EG.

Neth J Med. 2003 Dec;61(12):414-6.

44.

Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer.

de Vos FY, Bos AM, Gietema JA, Pras E, Van der Zee AG, de Vries EG, Willemse PH.

Anticancer Res. 2004 Jan-Feb;24(1):345-8.

45.

Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage.

de Vos FY, Nuver J, Willemse PH, van der Zee AG, Messerschmidt J, Burgerhof JG, de Vries EG, Gietema JA.

Eur J Cancer. 2004 Mar;40(5):696-700.

PMID:
15010070

Supplemental Content

Loading ...
Support Center